Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 86 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors.
Venkatachalam A, Correia C, Peterson KL, Hou X, Schneider PA, Strathman AR, Flatten KS, Sine CC, Balczewski EA, McGehee CD, Larson MC, Duffield LN, Meng XW, Vincelette ND, Ding H, Oberg AL, Couch FJ, Swisher EM, Li H, [...] Kaufmann SH
Mol Cancer, 23(1):224, 07 Oct 2024
Cited by: 0 articles | PMID: 39375715 | PMCID: PMC11457406
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer
Rodman EP, Emch MJ, Hou X, Bajaj A, Pearson NA, John AJ, Ortiz Y, Bass AD, Singh S, Baldassarre G, Kaufmann SH, Weroha SJ, Hawse JR
bioRxiv, 09 Jun 2024
Cited by: 0 articles | PPR: PPR864427
Add to export list Preprint
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.
Taya M, Hou X, Veneris JT, Kazi N, Larson MC, Maurer MJ, Heinzen EP, Chen H, Lastra R, Oberg AL, Weroha SJ, Fleming GF, Conzen SD
J Gynecol Oncol, 14 Jun 2024
Cited by: 0 articles | PMID: 38909640
Add to export list
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Kalogera E, Nevala WK, Finnes HD, Suman VJ, Schimke JM, Strand CA, Kottschade LA, Kudgus RA, Buhrow SA, Becher LR, Geng L, Glaser GE, Grudem ME, Jatoi A, Klampe CM, Kumar A, Langstraat CL, McWilliams RR, Wahner Hendrickson AE, [...] Block MS
Clin Cancer Res, 30(12):2623-2635, 01 Jun 2024
Cited by: 1 article | PMID: 38530846
Add to export list
Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
Hu C, Nagaraj AB, Shimelis H, Montalban G, Lee KY, Huang H, Lumby CA, Na J, Susswein LR, Roberts ME, Marshall ML, Hiraki S, LaDuca H, Chao E, Yussuf A, Pesaran T, Neuhausen SL, Haiman CA, Kraft P, [...] Couch FJ
Cancer Res, 83(15):2557-2571, 01 Aug 2023
Cited by: 3 articles | PMID: 37253112 | PMCID: PMC10390864
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling.
Sandoval L, Mohammed Ismail W, Mazzone A, Dumbrava M, Fernandez J, Munankarmy A, Lasho T, Binder M, Simon V, Kim KH, Chia N, Lee JH, Weroha SJ, Patnaik M, Gaspar-Maia A
Genes (Basel), 14(6):1245, 10 Jun 2023
Cited by: 2 articles | PMID: 37372428 | PMCID: PMC10297939
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling
Sandoval L, Mohammed Ismail W, Mazzone A, Dumbrava M, Fernandez J, Munankarmy A, Lasho T, Binder M, Simon V, Kim KH, Chia N, Lee JH, Weroha SJ, Patnaik MM, Gaspar-Maia A
Preprints.org, 08 May 2023
Cited by: 0 articles | PPR: PPR656531
Add to export list Preprint v1
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Shafa A, Watkins AB, McGree ME, Weroha SJ, Wahner Hendrickson AE, Block MS, Langstraat CL, McBane RD, Bakkum-Gamez JN, Kumar A
Gynecol Oncol, 176:36-42, 11 Jul 2023
Cited by: 2 articles | PMID: 37442024
Add to export list
Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile.
Gonzalez-Bosquet J, Weroha SJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Dowdy SC, Famuyide AO, Kipp BR, Halling KC, Yadav S, Couch FJ, Podratz KC
Front Oncol, 13:1105504, 23 May 2023
Cited by: 1 article | PMID: 37287928 | PMCID: PMC10242089
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Epigenomics may begin to explain in vitro differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer.
El Khoury LY, Lin WH, Smadbeck JB, Barrett MT, Sadeghian D, McCune AF, Karagouga G, Cheville JC, Harris FR, Kinsella LM, Feathers RW, Schafer Klein JL, Walther-Antonio MR, Johnson SH, Penheiter AR, Cucinella G, Schivardi G, Bhagwate A, Borad MJ, [...] Larish AM
Epigenomics, 15(5):283-292, 01 Mar 2023
Cited by: 0 articles | PMID: 37212177
Add to export list
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, [...] Barker HE
Cancer Res, 82(23):4457-4473, 01 Dec 2022
Cited by: 9 articles | PMID: 36206301 | PMCID: PMC9716257
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J, Weroha SJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Dowdy SC, Famuyide AO, Kipp BR, Halling KC, Yadav S, Couch FJ, Podratz KC
PLoS One, 17(12):e0278408, 01 Dec 2022
Cited by: 1 article | PMID: 36454788 | PMCID: PMC9714733
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model.
Aalam SMM, Tang X, Song J, Ray U, Russell SJ, Weroha SJ, Bakkum-Gamez J, Shridhar V, Sherman ME, Eaves CJ, Knapp DJHF, Kalari KR, Kannan N
NAR Cancer, 4(3):zcac022, 22 Jul 2022
Cited by: 1 article | PMID: 35875052 | PMCID: PMC9303272
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Garzon S, Grassi T, Mariani A, Kollikonda S, Weaver AL, McGree ME, Petersen IA, Weroha SJ, Glaser GE, Langstraat CL, Amarnath SR, AlHilli MM
Gynecol Oncol, 167(3):444-451, 14 Oct 2022
Cited by: 5 articles | PMID: 36244826
Add to export list
Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer.
Ding D, Zheng R, Tian Y, Jimenez R, Hou X, Weroha SJ, Wang L, Shi L, Huang H
Nat Commun, 13(1):6311, 23 Oct 2022
Cited by: 4 articles | PMID: 36274096 | PMCID: PMC9588789
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Clemente V, Hoshino A, Shetty M, Nelson A, Erickson BK, Baker R, Rubin N, Khalifa M, Weroha SJ, Lou E, Bazzaro M
Cancer Res Commun, 2(8):784-794, 10 Aug 2022
Cited by: 4 articles | PMID: 36082022 | PMCID: PMC9451103
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.
Cotler MJ, Ramadi KB, Hou X, Christodoulopoulos E, Ahn S, Bashyam A, Ding H, Larson M, Oberg AL, Whittaker C, Jonas O, Kaufmann SH, Weroha SJ, Cima MJ
Transl Oncol, 21:101427, 26 Apr 2022
Cited by: 1 article | PMID: 35472731 | PMCID: PMC9136609
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM
Cancer Res, 82(2):307-319, 22 Nov 2021
Cited by: 7 articles | PMID: 34810199 | PMCID: PMC8770599
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.
Kurnit KC, Steiner M, Lastra RR, Weroha SJ, Cursio J, Lengyel E, Fleming GF, Conzen SD
Gynecol Oncol Rep, 41:100987, 27 Apr 2022
Cited by: 2 articles | PMID: 35519002 | PMCID: PMC9065886
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.
Ray U, Jung DB, Jin L, Xiao Y, Dasari S, Sarkar Bhattacharya S, Thirusangu P, Staub JK, Roy D, Roy B, Weroha SJ, Hou X, Purcell JW, Bakkum-Gamez JN, Kaufmann SH, Kannan N, Mitra AK, Shridhar V
Cancer Res, 82(6):1038-1054, 01 Mar 2022
Cited by: 25 articles | PMID: 34654724 | PMCID: PMC8930558
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, [...] Paulovich AG
Cell Rep Med, 2(12):100471, 21 Dec 2021
Cited by: 24 articles | PMID: 35028612 | PMCID: PMC8714940
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.
Liu D, Hou X, Wu W, Zanfagnin V, Li Y, Correia C, Zhao Z, Zhao C, Liu Z, Zhang T, Fang Z, Wang H, Xu C, Weroha SJ, Kaufmann SH, Dai H
Cell Death Dis, 12(8):789, 12 Aug 2021
Cited by: 3 articles | PMID: 34385422 | PMCID: PMC8361168
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
CHFR and Paclitaxel Sensitivity of Ovarian Cancer.
Wahner Hendrickson AE, Visscher DW, Hou X, Goergen KM, Atkinson HJ, Beito TG, Negron V, Lingle WL, Bruzek AK, Hurley RM, Wagner JM, Flatten KS, Peterson KL, Schneider PA, Larson MC, Maurer MJ, Kalli KR, Oberg AL, Weroha SJ, Kaufmann SH
Cancers (Basel), 13(23):6043, 30 Nov 2021
Cited by: 1 article | PMID: 34885153 | PMCID: PMC8657201
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.
Liu D, Hou X, Wu W, Zafagnin V, Li Y, Correia C, Zhao Z, Zhao C, Liu Z, Zhang T, Fang Z, Wang H, Xu C, Weroha SJ, Kaufmann SH, Dai H
Cell Death Dis, 12(11):1002, 26 Oct 2021
Cited by: 0 articles | PMID: 34702806 | PMCID: PMC8548556
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, [...] Scott CL
Cancer Res, 81(18):4709-4722, 28 Jul 2021
Cited by: 42 articles | PMID: 34321239
Add to export list

1-25 of 86 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors.

Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer

Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.

A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.

Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.

Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling.

Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling

Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?

Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile.

Epigenomics may begin to explain in vitro differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer.

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.

DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model.

Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer.

GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.

Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.

High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.

Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.

Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.

CHFR and Paclitaxel Sensitivity of Ovarian Cancer.

Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

Partnerships & funding